| ABT-267, ABT 333, ABT-450 and Ritonavir |
AbbVie |
June 2017 |
|
| Bedaquiline (TMC207) |
Janssen Research & Development |
October 2025 |
|
| Delamanid (OPC-67683) |
Otsuka |
August 2024 |
|
| Dolutegravir (GSK1349572) |
ViiV Healthcare |
October 2025 |
|
| Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) |
Gilead Sciences |
December 2016 |
YES |
| Glecaprevir/Pibrentasvir |
AbbVie |
December 2025 |
|
| GSK1265744 (Cabotegravir) - New |
ViiV Healthcare |
January 2026 |
|
| Pretomanid (PA-824) - New |
Global Alliance for TB Drug Development (TB Alliance) |
December 2025 |
|
| Quercefit (Quercetin Phospholipid) |
Indena |
February 2025 |
|
| Remdesivir (Veklury) |
Gilead Sciences |
June 2021 |
|
| Rilpivirine (TMC278, Edurant) |
Janssen Research & Development |
June 2025 |
|
| Sutezolid |
Global Alliance for TB Drug Development (TB Alliance) |
April 2025 |
|
| TBI-223 |
Global Alliance for TB Drug Development (TB Alliance) |
October 2023 |
|
| Tenofovir |
Conrad |
November 2024 |
|
| Tenofovir Disoproxil Fumarate/Emtricitabine/Levonorgestrel/ Ethinyl estradiol (Ahana) |
Viatris |
August 2024 |
|
| Vorinostat (Zolinza) |
Merck |
August 2013 |
|
